Keely Cox
Acute Care · Meridian, IDNPI 1952955502
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 149 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 32.9% of the total. Among acute care clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 149 payments — averaging $32.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$333
- EMD Serono, Inc.$255
- Biogen$235
- SK Life Science, Inc.$227
- Genentech USA, Inc.$211
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$180%
- Food & beverage$4,897100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 66 | $1,617 |
| Teva Pharmaceuticals USA, Inc. | 6 | $333 |
| EMD Serono, Inc. | 8 | $255 |
| Biogen | 6 | $235 |
| SK Life Science, Inc. | 2 | $227 |
| Genentech USA, Inc. | 7 | $211 |
| Biohaven Pharmaceuticals, Inc. | 3 | $207 |
| Genentech, Inc. | 4 | $199 |
| Novartis | 2 | $189 |
| Argenx US, Inc. | 3 | $174 |
| Kyowa Kirin, Inc. | 2 | $154 |
| Pfizer | 2 | $140 |
| E.r. Squibb & Sons, L.L.C. | 1 | $109 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $85 |
| Lilly USA, LLC | 4 | $77 |
| Neurocrine Biosciences, Inc. | 3 | $66 |
| Livanova USA, Inc. | 1 | $65 |
| Amgen | 2 | $58 |
| Ipsen Biopharmaceuticals, Inc | 2 | $49 |
| Acadia Pharmaceuticals Inc | 2 | $49 |
| Upsher-smith Laboratories LLC | 3 | $49 |
| Bristol Myers Squibb | 2 | $46 |
| Sunovion Pharmaceuticals Inc. | 3 | $44 |
| UCB, Inc. | 2 | $43 |
| Amneal Pharmaceuticals LLC | 2 | $43 |
| Acorda Therapeutics, Inc | 2 | $39 |
| AstraZeneca | 2 | $34 |
| Sanofi | 1 | $27 |
| Johnson & Johnson | 1 | $23 |
| CSL Behring | 1 | $21 |
| GE HealthCare | 1 | $16 |
| Neurelis, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,915 in reported general payments places this provider in the 95th percentile of 35 acute care providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 115 | $90,488 |
| Avonex (4 Pack)Interferon Beta-1a | 11 | $87,048 |
| UbrelvyUbrogepant | 59 | $73,301 |
| EpidiolexCannabidiol (Cbd) | 16 | $57,757 |
| Dimethyl Fumarate | 35 | $57,522 |
| Nurtec OdtRimegepant Sulfate | 45 | $54,392 |
| QuliptaAtogepant | 28 | $31,688 |
| Emgality PenGalcanezumab-Gnlm | 35 | $27,377 |
| GlatopaGlatiramer Acetate | 14 | $23,850 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 20 | $19,246 |
| Ajovy SyringeFremanezumab-Vfrm | 21 | $15,111 |
| ReyvowLasmiditan Succinate | 16 | $11,710 |
| Sumatriptan Succinate | 116 | $11,566 |
| Lacosamide | 86 | $11,518 |
| Levetiracetam | 296 | $9,975 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $1,617 | $104,98987 claims |
| BiogenAvonex (4 Pack) | $235 | $87,04811 claims |
| PfizerNurtec Odt | $140 | $54,39245 claims |
| Lilly USA, LLCReyvow | $77 | $11,71016 claims |
| Upsher-smith Laboratories LLCTopiramate | $49 | $2,587136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 acute care providers in Idaho.
Other acute care in Meridian
- Kristie TamerMeridian$585
- Erin GrosslightMeridian$392
- Elaine HumphriesMeridian$179
- Aimee BrooksMeridian$131
- Izabela HarutyunyanPocatello$9K
- Lydia MoorBoise$3K
- Nathan BurkeBoise$3K
- Sarah FrankCoeur D Alene$2K
- Rachel DavisBoise$2K
- Ryan HarveyNampa$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.